Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $13,132.35 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $3.15, for a total transaction of $13,132.35. Following the completion of the transaction, the insider now owns 134,921 shares in the company, valued at approximately $425,001.15. The trade was a 3.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $3.49, for a total transaction of $12,836.22.

Amylyx Pharmaceuticals Stock Up 4.6 %

Amylyx Pharmaceuticals stock traded up $0.14 during mid-day trading on Wednesday, hitting $3.20. 684,184 shares of the company’s stock traded hands, compared to its average volume of 1,827,482. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95. The firm has a 50 day moving average price of $3.64 and a 200 day moving average price of $3.82. The company has a market cap of $219.35 million, a PE ratio of -0.84 and a beta of -0.54.

Analysts Set New Price Targets

AMLX has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Finally, Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp grew its position in Amylyx Pharmaceuticals by 234.9% in the 4th quarter. Mackenzie Financial Corp now owns 111,310 shares of the company’s stock valued at $421,000 after buying an additional 78,070 shares in the last quarter. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth approximately $45,000. Two Sigma Investments LP boosted its holdings in shares of Amylyx Pharmaceuticals by 77.4% in the fourth quarter. Two Sigma Investments LP now owns 651,517 shares of the company’s stock valued at $2,463,000 after acquiring an additional 284,280 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at approximately $249,000. Finally, Orbimed Advisors LLC bought a new stake in Amylyx Pharmaceuticals during the fourth quarter worth approximately $1,315,000. 95.84% of the stock is currently owned by institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.